DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On March30, 2017, Dicerna Pharmaceuticals, Inc., a Delaware
corporation (the Company), issued a press release announcing its
financial results for the quarter and year ended December31,
2016. A copy of the press release is furnished herewith as
Exhibit 99.1.
On March23, 2017, the Company announced that it would hold a
conference call and live audio webcast at 4:30 p.m., eastern
time, March30, 2017, to discuss its financial results and provide
a general business update.
The information in this Form 8-K (including Exhibit 99.1 attached
hereto) is being furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the liability
of that section, nor shall such information be deemed to be
incorporated by reference in any registration statement or other
document filed under the Securities Act of 1933, as amended, or
the Exchange Act, except as otherwise stated in such filing.
| Item9.01 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release titled Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results issued by Dicerna Pharmaceuticals, Inc. on March 30, 2017. |
About DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET). DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA) Recent Trading Information
DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA) closed its last trading session 00.00 at 2.70 with 83,182 shares trading hands.